Human papillomavirus (HPV) vaccine market shaping roadmap
INSIGHT PAPER | March 2024
This insight paper provides a non-technical summary of that document. It highlights how working towards a series of key objectives and target outcomes can help achieve a healthy HPV vaccine market, and how doing so can play a major role in turning the ambitious vision of consigning cervical cancer to history into a worldwide reality.
The Vaccine Investment Strategy (VIS)
BACKGROUND PAPER | February 2024
The Vaccine Investment Strategy (VIS) enables Gavi to maximise the number of lives it helps save and the number of people whose health it improves, while facilitating long‑term planning for partners, donors, manufacturers and Gavi‑supported countries.
Learning from COVID-19 to support vaccine delivery during future health emergencies
ANALYSIS PAPER | February 2024
This analysis paper describes the circumstances in which the Gavi Secretariat took on a broader set of roles and responsibilities in supporting COVID-19 vaccine delivery than originally intended and summarises the nature of those contributions.
Coordination in a crisis: Lessons managing the COVAX Strategic Coordination Office (2021–2023)
WHITE PAPER | December 2023
Drawing upon experiences gained during the COVID-19 pandemic in coordinating the COVAX Strategic Coordination Office (SCO), this paper proposes lessons for future pandemic responses, as well as what might be maintained during intra-pandemic periods, to better prepare for future emergencies.
Raising Generation ImmUnity: The 2023 Mid-Term Review Report
REPORT | June 2023
This report uses data from the first two years of the Alliance’s 2021-2025 strategic period to chart progress against the 2019 Investment Opportunity. The Alliance is on track to meet the majority of the key commitments made to donors. This includes supporting countries to immunise an additional 300 million children by 2025, delivering 3.2 billion vaccines, saving more than seven million lives and generating economic benefits of US$ 80-100 billion.
A preliminary assessment of COVAX’s impact in lower-income countries
WHITE PAPER | May 2023
Approximately 90% of COVAX-delivered COVID-19 doses have gone to lower-income economies. This represents the fastest and most complex global deployment of vaccines ever. But in terms of achieving equitable access during this pandemic, how successful has it been and where have its impacts been the greatest?
Malaria vaccine market shaping roadmap
WHITE PAPER | April 2023
The development of the world’s first safe and effective malaria vaccine is a truly historic breakthrough. However, to harness its potential to help save many of the more than 600,000 lives claimed by the disease every year, much work still needs to be done. That’s why Gavi, the Vaccine Alliance, is setting out detailed plans to boost supplies of malaria vaccines, lower their costs, improve our understanding of demand, support vaccination programmes and create a supportive environment for future malaria vaccine innovation.
Building an emergency response decision-making framework for outbreaks of pandemic potential
DISCUSSION PAPER | April 2023
When an outbreak of an infectious disease starts to escalate, how should global health organisations decide on if, when and how to launch a response? To this end, Gavi is working with partners to develop a decision-making framework for outbreaks of pandemic potential that will define optimum interventions, specific to the outbreak, and unlock critical financing in response.
10 Learnings for the Alliance from the COVAX Humanitarian Buffer
DISCUSSION PAPER | February 2023
The following 10 learnings highlight the ways in which the COVAX Humanitarian Buffer (HB) and COVAX’s broader learnings in reaching humanitarian settings can contribute to both the Alliance’s work in routine immunisation, future preparedness and response efforts.
Gavi Expanding Sustainable Vaccine Manufacturing in Africa 2022
WHITE PAPER | 2 November 2022
The pandemic has highlighted new and pressing challenges to regional vaccine supply resilience as a critical factor in global health security. While 1.8 billion doses1 of COVID-19 vaccine have been shipped under COVAX, including 0.6 billion to Africa, early delays in obtaining doses on the African continent stimulated new resolve to address future supply security.
COVAX: key learnings for future pandemic preparedness and response
WHITE PAPER | 14 September 2022
Drawing on COVAX’s unique experience enabling an unprecedented global rollout at scale during a pandemic, this paper outlines the key challenges the mechanism faced in seeking to ensure equitable access to COVID-19 vaccines, the actions it took in response and recommendations for the future.
A New Era of Vaccine Manufacturing in Africa
WHITE PAPER | 22 June 2022
One of the prominent issues exposed by the COVID-19 pandemic is the urgent need to further diversify global vaccine manufacturing, particularly with regards to Africa. With the political realities of nationalism, trade barriers, and the absence of regional manufacturing capability and capacity, rapid and equitable global access to life-saving vaccines can be compromised, leading to delays that put lives at risk.
Taking stock of humanitarian access to pandemic vaccines
DISCUSSION PAPER | 22 June 2022
COVAX was launched in 2020 with equity as its foundational principle, and fundamental to its design from the outset was a vision to address the most unpredictable and hardest to fill gaps in global COVID-19 vaccine access.
All Products
Last updated: 8 Apr 2024